Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone

Kashif Shaikh; Susan S. Ellenberg; Rine Nakanishi; Peter J. Snyder; Juhwan Lee; Nanette K. Wenger; Cora E. Lewis; Ronald S. Swerdloff; Peter Preston; Sajad Hamal; Alisa Stephens-Sheilds; Shalender Bhasin; Lavanya Cherukuri; Jane A. Cauley; Jill P. Crandall; Glenn R. Cunningham; Kristine E. Ensrud; Alvin M. Matsumoto; Mark E. Molich; Venkata M. Alla; Divya Birudaraju; Negin Nezarat; Kelash Rai; Shone Almeida; Sion K. Roy; Mohammad Sheikh; George Trad; Mathew J. Budoff

doi:10.1210/clinem/dgz242

Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone

Kashif Shaikh, Susan S. Ellenberg, Rine Nakanishi, Peter J. Snyder, Juhwan Lee, Nanette K. Wenger, Cora E. Lewis, Ronald S. Swerdloff, Peter Preston, Sajad Hamal, Alisa Stephens-Sheilds, Shalender Bhasin, Lavanya Cherukuri, Jane A. Cauley, Jill P. Crandall, Glenn R. Cunningham, Kristine E. Ensrud, Alvin M. Matsumoto, Mark E. Molich, Venkata M. AllaDivya Birudaraju, Negin Nezarat, Kelash Rai, Shone Almeida, Sion K. Roy, Mohammad Sheikh, George Trad, Mathew J. Budoff

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objective: Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods: The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results: Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion: Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.

Original language	English (US)
Article number	dgz242
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	105
Issue number	7
DOIs	https://doi.org/10.1210/clinem/dgz242
State	Published - Jul 1 2020

Keywords

Coronary artery disease
Noncalcified coronary artery plaque
Testosterone replacement

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1210/clinem/dgz242

Cite this

Shaikh, K., Ellenberg, S. S., Nakanishi, R., Snyder, P. J., Lee, J., Wenger, N. K., Lewis, C. E., Swerdloff, R. S., Preston, P., Hamal, S., Stephens-Sheilds, A., Bhasin, S., Cherukuri, L., Cauley, J. A., Crandall, J. P., Cunningham, G. R., Ensrud, K. E., Matsumoto, A. M., Molich, M. E., ... Budoff, M. J. (2020). Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone. Journal of Clinical Endocrinology and Metabolism, 105(7), Article dgz242. https://doi.org/10.1210/clinem/dgz242

Shaikh, K, Ellenberg, SS, Nakanishi, R, Snyder, PJ, Lee, J, Wenger, NK, Lewis, CE, Swerdloff, RS, Preston, P, Hamal, S, Stephens-Sheilds, A, Bhasin, S, Cherukuri, L, Cauley, JA, Crandall, JP, Cunningham, GR, Ensrud, KE, Matsumoto, AM, Molich, ME, Alla, VM, Birudaraju, D, Nezarat, N, Rai, K, Almeida, S, Roy, SK, Sheikh, M, Trad, G & Budoff, MJ 2020, 'Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone', Journal of Clinical Endocrinology and Metabolism, vol. 105, no. 7, dgz242. https://doi.org/10.1210/clinem/dgz242

@article{152548be204d493dab7097a239646590,

title = "Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone",

abstract = "Objective: Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods: The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results: Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion: Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.",

keywords = "Coronary artery disease, Noncalcified coronary artery plaque, Testosterone replacement",

author = "Kashif Shaikh and Ellenberg, {Susan S.} and Rine Nakanishi and Snyder, {Peter J.} and Juhwan Lee and Wenger, {Nanette K.} and Lewis, {Cora E.} and Swerdloff, {Ronald S.} and Peter Preston and Sajad Hamal and Alisa Stephens-Sheilds and Shalender Bhasin and Lavanya Cherukuri and Cauley, {Jane A.} and Crandall, {Jill P.} and Cunningham, {Glenn R.} and Ensrud, {Kristine E.} and Matsumoto, {Alvin M.} and Molich, {Mark E.} and Alla, {Venkata M.} and Divya Birudaraju and Negin Nezarat and Kelash Rai and Shone Almeida and Roy, {Sion K.} and Mohammad Sheikh and George Trad and Budoff, {Mathew J.}",

year = "2020",

month = jul,

day = "1",

doi = "10.1210/clinem/dgz242",

language = "English (US)",

volume = "105",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "7",

}

TY - JOUR

T1 - Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone

AU - Shaikh, Kashif

AU - Ellenberg, Susan S.

AU - Nakanishi, Rine

AU - Snyder, Peter J.

AU - Lee, Juhwan

AU - Wenger, Nanette K.

AU - Lewis, Cora E.

AU - Swerdloff, Ronald S.

AU - Preston, Peter

AU - Hamal, Sajad

AU - Stephens-Sheilds, Alisa

AU - Bhasin, Shalender

AU - Cherukuri, Lavanya

AU - Cauley, Jane A.

AU - Crandall, Jill P.

AU - Cunningham, Glenn R.

AU - Ensrud, Kristine E.

AU - Matsumoto, Alvin M.

AU - Molich, Mark E.

AU - Alla, Venkata M.

AU - Birudaraju, Divya

AU - Nezarat, Negin

AU - Rai, Kelash

AU - Almeida, Shone

AU - Roy, Sion K.

AU - Sheikh, Mohammad

AU - Trad, George

AU - Budoff, Mathew J.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Objective: Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods: The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results: Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion: Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.

AB - Objective: Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods: The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results: Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion: Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.

KW - Coronary artery disease

KW - Noncalcified coronary artery plaque

KW - Testosterone replacement

UR - http://www.scopus.com/inward/record.url?scp=85084721196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084721196&partnerID=8YFLogxK

U2 - 10.1210/clinem/dgz242

DO - 10.1210/clinem/dgz242

M3 - Article

C2 - 31784747

AN - SCOPUS:85084721196

SN - 0021-972X

VL - 105

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 7

M1 - dgz242

ER -

Biomarkers and noncalcified coronary artery plaque progression in older men treated with testosterone

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this